• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BLU

    BELLUS Health Inc.

    Subscribe to $BLU
    $BLU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: bellushealth.com

    Recent Analyst Ratings for BELLUS Health Inc.

    DatePrice TargetRatingAnalyst
    4/19/2023Outperform → Sector Perform
    RBC Capital Mkts
    2/24/2022$14.00 → $16.00Buy
    HC Wainwright & Co.
    12/13/2021$12.00 → $20.00Outperform
    Evercore ISI Group
    12/7/2021$9.00 → $11.00Outperform
    RBC Capital
    10/18/2021$8.00 → $9.00Outperform
    RBC Capital
    9/14/2021$10.00 → $14.00Buy
    HC Wainwright & Co.
    7/29/2021$9.00Buy
    BTIG Research
    See more ratings

    BELLUS Health Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BELLUS Health downgraded by RBC Capital Mkts

      RBC Capital Mkts downgraded BELLUS Health from Outperform to Sector Perform

      4/19/23 8:02:26 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BELLUS Health with a new price target

      HC Wainwright & Co. reiterated coverage of BELLUS Health with a rating of Buy and set a new price target of $16.00 from $14.00 previously

      2/24/22 6:21:58 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI Group reiterated coverage on BELLUS Health with a new price target

      Evercore ISI Group reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $20.00 from $12.00 previously

      12/13/21 10:40:28 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on BELLUS Health with a new price target

      RBC Capital reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $11.00 from $9.00 previously

      12/7/21 6:45:34 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on BELLUS Health with a new price target

      RBC Capital reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

      10/18/21 8:35:51 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BELLUS Health with a new price target

      HC Wainwright & Co. reiterated coverage of BELLUS Health with a rating of Buy and set a new price target of $14.00 from $10.00 previously

      9/14/21 6:08:58 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on BELLUS Health with a new price target

      BTIG Research initiated coverage of BELLUS Health with a rating of Buy and set a new price target of $9.00

      7/29/21 9:53:58 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital initiated coverage on BELLUS Health with a new price target

      RBC Capital initiated coverage of BELLUS Health with a rating of Outperform and set a new price target of $8.00

      1/29/21 6:54:35 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    BELLUS Health Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by BELLUS Health Inc.

      15-12G - BELLUS Health Inc. (0001259942) (Filer)

      7/10/23 8:00:11 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BELLUS Health Inc.

      S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

      6/28/23 5:20:23 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BELLUS Health Inc.

      S-8 POS - BELLUS Health Inc. (0001259942) (Filer)

      6/28/23 4:57:20 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BELLUS Health Inc.

      6-K - BELLUS Health Inc. (0001259942) (Filer)

      6/28/23 2:42:19 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BELLUS Health Inc.

      6-K - BELLUS Health Inc. (0001259942) (Filer)

      6/28/23 11:05:50 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BELLUS Health Inc.

      6-K - BELLUS Health Inc. (0001259942) (Filer)

      6/16/23 4:21:28 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BELLUS Health Inc.

      6-K - BELLUS Health Inc. (0001259942) (Filer)

      6/6/23 4:05:34 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BELLUS Health Inc.

      6-K - BELLUS Health Inc. (0001259942) (Filer)

      6/2/23 4:25:19 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BELLUS Health Inc.

      6-K - BELLUS Health Inc. (0001259942) (Filer)

      5/19/23 5:27:10 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BELLUS Health Inc.

      6-K - BELLUS Health Inc. (0001259942) (Filer)

      5/16/23 5:04:42 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    BELLUS Health Inc. Financials

    Live finance-specific insights

    See more
    • Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

      LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

      6/28/23 10:57:00 AM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

      Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.5%); treatment emergent adverse event profile comparable to placebo Company also provides an update on its P2X3 pipeline and BLU-5937 Phase 2a trial for the treatment of chronic pruritus Company to host conference call and webcast at 8:00 a.m. ET BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC"

      12/13/21 7:00:00 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    BELLUS Health Inc. Leadership Updates

    Live Leadership Updates

    See more
    • OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

      NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

      1/4/23 8:00:00 AM ET
      $BLU
      $GKOS
      $INSP
      $NTLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

      LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas. “Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” c

      3/24/21 7:00:00 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    BELLUS Health Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BELLUS Health Inc.

      SC 13G - BELLUS Health Inc. (0001259942) (Subject)

      1/30/24 10:56:14 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

      SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

      8/14/23 5:01:58 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BELLUS Health Inc.

      SC 13G - BELLUS Health Inc. (0001259942) (Subject)

      3/30/23 4:05:24 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

      SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

      2/14/23 4:45:46 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

      SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

      2/14/23 4:06:08 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

      SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

      2/14/23 2:32:29 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

      SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

      2/14/23 10:17:41 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BELLUS Health Inc. (Amendment)

      SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)

      2/14/23 8:26:46 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BELLUS Health Inc.

      SC 13G - BELLUS Health Inc. (0001259942) (Subject)

      2/13/23 4:30:07 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BELLUS Health Inc.

      SC 13G - BELLUS Health Inc. (0001259942) (Subject)

      2/3/23 11:28:59 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    BELLUS Health Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

      LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R

      6/28/23 10:57:00 AM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders

      BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the "Special Meeting") held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:GSK, LSE: GSK))) ("GSK"), will acquire, for a purchase price of US$14.75 in cash per share, all of the issued and outstanding common shares of BELLUS (the

      6/16/23 1:50:00 PM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition

      Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co

      5/16/23 5:01:00 PM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights

      - Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%; transaction expected to close in Q3 2023 – BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the quarter ended March 31, 2023. "Our merger agreement with GSK underscores our corporate and clini

      5/12/23 4:01:00 PM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Announces Meeting Updates

      BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 billion pursuant to a plan of arrangement (the "Acquisition Meeting"). The Company will hold the Acquisition Meeting to consider the acquisition on June 16, 2023. The Company's Board of Directors has unanimously recommended that

      4/26/23 6:00:00 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

      Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2026 Accretive to adjusted EPS from 2027 with significant sales potential through 2031 GSK plc (NYSE:GSK) and BELLUS Health Inc. (NASDAQ:BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share

      4/18/23 12:11:00 PM ET
      $BLU
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation

      Once-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation Extended-Release formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reported Additional data to be presented at a future medical conference BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today announced positive data from its

      4/5/23 7:00:00 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health Reports Year 2022 Financial Results and Business Highlights

      - Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024 - - Ended year with US$337.1 million in cash, cash equivalents and short-term investments; cash runway extends to the second half of 2025 and through expected topline results of both CALM-1 and CALM-2 trials - BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the ye

      3/21/23 4:30:00 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference

      BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in the Respiratory/Infections panel discussion at the Cowen 43rd Annual Health Care Conference, being held March 6 - 8, 2023 in Boston, MA. Respiratory/Infections Panel Discussion Details: Event: Cowen 43rd Annual Health Care Conference Date/Time: Wednesday, March 8th, 2023 at 10:30 a.m. ET Location: Boston, MA A webcast of the panel

      3/1/23 7:00:00 AM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting

      BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held in San Antonio, Texas from February 24-27, 2023. Poster Presentation Details: Title: Burden of Cough in Refractory Chronic Cough Populations Enrolled in A Phase 2b Study of the P2X3 Antagonist BLU-5937 Dat

      2/8/23 4:01:00 PM ET
      $BLU
      Biotechnology: Pharmaceutical Preparations
      Health Care